| 徐芬芬,赖林强,叶泽康,等.静脉化疗联合支气管动脉化疗栓塞术治疗中晚期非小细胞肺癌的疗效和安全性分析[J].肿瘤学杂志,2025,31(4):305-310. |
| 静脉化疗联合支气管动脉化疗栓塞术治疗中晚期非小细胞肺癌的疗效和安全性分析 |
| Efficacy and Safety of Intravenous Chemotherapy Combined with Bronchial Arterial Chemoembolization in Treatment of Advanced Non-Small Cell Lung Cancer |
| 投稿时间：2025-01-10 |
| DOI：10.11735/j.issn.1671-170X.2025.04.B005 |
|
 |
| 中文关键词: 癌，非小细胞肺 静脉化疗 支气管动脉化疗栓塞术 疗效 不良事件 |
| 英文关键词:carcinoma, non-small cell lung intravenous chemotherapy bronchial arterial chemoembolization adverse event |
| 基金项目:丽水市科技计划项目（2023SJZC028）；浙江省医学会临床医学专项资金项目（2022ZYC-A263）；湖北陈孝平科技发展基金会槐耳专项基金项目（CXPJJH122002-015）；吴阶平医学基金会临床科研专项资助基金（320.6750.2023-05-18） |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘 要：［目的］ 观察静脉化疗联合支气管动脉化疗栓塞术（bronchial arterial chemoembolization，BACE）治疗中晚期非小细胞肺癌的疗效和安全性。［方法］ 回顾性收集2019年7月至2023年4月期间丽水市中心医院收治的中晚期非小细胞肺癌患者132例，其中化疗联合BACE治疗65例（联合组），单纯化疗67例（化疗组）。主要研究终点为疾病无进展生存期，次要研究终点包括：客观缓解率、疾病控制率、不良事件发生率。采用单/多因素Cox回归分析，确定影响疾病无进展生存的独立危险因素。［结果］ 基线资料比较发现两组患者仅肿瘤数目存在统计学差异（P<0.05）。短期疗效方面，联合组的疾病控制率和客观缓解率分别为87.7%和64.6%，均优于化疗组的70.1%和46.3%（P=0.014、0.034）。联合组中位无进展生存期为7个月［95%置信区间（confidence interval，CI）：6.05~7.95］优于化疗组的4个月（95%CI：3.01~4.99）（P<0.001）。多因素Cox回归分析显示化疗联合BACE治疗是疾病无进展生存时间的独立有利因素。不良反应发生率方面，随访期间联合组治疗后出现乏力、恶心呕吐和骨髓抑制发生率均显著低于化疗组（P<0.05）。［结论］ 化疗联合BACE治疗中晚期非小细胞肺癌近期疗效明显，且可显著降低治疗后乏力、恶心呕吐和骨髓抑制的发生率。 |
| 英文摘要: |
| Abstract： ［Objective］ To observe the efficacy and safety of intravenous chemotherapy and intravenous chemotherapy combined with bronchial arterial chemoembolization (BACE) in treatment of advanced non-small cell lung cancer (NSCLC). ［Methods］ Clinical data of 132 cases with advanced NSCLC admitted to Lishui Central Hospital between July 2019 and April 2023 were retrospectively analyzed， including 65 cases treated with chemotherapy combined with BACE (combination group) and 67 cases treated with chemotherapy alone (chemotherapy group). The primary study endpoint was progression-free survival (PFS)， and secondary study endpoints included objective response rate， disease control rate， and adverse event rate. Univariate and multivariate Cox regression analysis was used to determine the independent risk factors of PFS. ［Results］ There was no significant difference in general clinical data between two groups， except the number of tumors (P<0.05). The disease control rate and objective response rate of the combination group were significantly higher than those of chemotherapy group (87.7% vs 70.1%， P=0.014 and 64.6% vs 46.3%， P=0.034). The median PFS in the combination group was 7 months ［95% confidence interval (CI)： 6.05~7.95］， which was significantly higher than that of chemotherapy group (4 months， 95%CI： 3.01~4.99)(P<0.001). Multivariate Cox regression analysis showed that the combined BACE treatment was an independent protective factor for PFS of patients. The incidence of fatigue， nausea， vomiting， and bone marrow suppression in the combination group was significantly lower than that in the chemotherapy group (P<0.05). ［Conclusion］ Chemotherapy combined with BACE has better short-term efficacy and significantly reduces the incidence of adverse reactions in the treatment of patients with advanced NSCLC. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |